Clinical Trial Update: Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

View source ↗

Summary

A terminated clinical trial evaluated lymphokine-activated killer cytotoxicity in patients undergoing interleukin-2 therapy for melanoma and kidney cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Loma Linda University | Conditions: Melanoma, Kidney Cancer | Status: TERMINATED